IHERO Study: Insurance, Health and Economic Resources Online for Emerging Adults with Type 1 Diabetes

Last updated: March 14, 2025
Sponsor: University Hospitals Cleveland Medical Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

Diabetes And Hypertension

Diabetes Mellitus, Type 1

Diabetes Mellitus Types I And Ii

Treatment

iHERO Toolkit Resource

Clinical Study ID

NCT06348160
STUDY20230187
  • Ages 18-30
  • All Genders

Study Summary

This research study aims to test a financial and health insurance iHERO Toolkit for young adults with type1 diabetes. The iHERO Toolkit was developed over one year with the type 1 diabetes community, The Diabetes Link organization, and experts. Now, the investigators want to understand the impact of the iHERO Toolkit on diabetes self-management, financial stress, and health insurance literacy outcomes. The investigators are doing this study because it will help to better understand how to support health insurance and financial stress and improve self-management outcomes in young adults with type 1 diabetes. The investigators want to understand how the iHERO Toolkit helps all young adults with diabetes, but especially those on Medicaid and who are racially or ethnically diverse. The investigators will ask participants to participate at four-time points over one year. For the first time, participants will fill out online enrollment and demographic forms and 9 surveys. The 9 surveys have 8-40 short questions each, estimated to take about 45 minutes. Participants will also be asked to complete a home A1c collection with a University Hospitals team member on Zoom.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age range: 18-30 years

  • Diagnosis of type 1 diabetes (T1D)

  • T1D duration for one year or longer

  • Geographical location: residing in the United States.

Exclusion

Exclusion Criteria:

  • Inability to answer questions due to cognitive status.

  • Inability to read or understand English.

  • Diagnosis of insulin-dependent diabetes that is not T1D such as cysticfibrosis-related diabetes, maturity-onset diabetes of the young, orinsulin-dependent type 2 diabetes.

Study Design

Total Participants: 192
Treatment Group(s): 1
Primary Treatment: iHERO Toolkit Resource
Phase:
Study Start date:
May 14, 2024
Estimated Completion Date:
March 31, 2027

Connect with a study center

  • Children's Hospital Los Angeles

    Los Angeles, California 90027
    United States

    Site Not Available

  • University of Florida Diabetes Institute

    Gainesville, Florida 32610
    United States

    Site Not Available

  • University Hospitals

    Cleveland, Ohio 44106
    United States

    Active - Recruiting

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania 19104
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.